← Back to Search

Corticosteroid

Treatment for Parkinsonism (RES Trial)

Phase 1 & 2
Waitlist Available
Led By Nicolaas Bohnen, MD
Research Sponsored by University of Michigan
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 60 or older (M/F)
Evidence of mild parkinsonian signs (incl. slow gait (< 1m/s))
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 7-13 days after beginning treatment
Awards & highlights

RES Trial Summary

This trial is investigating whether dopamine can help improve slow walking in older adults.

RES Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

RES Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~7-13 days after beginning treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and 7-13 days after beginning treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Average Gait Speed
Cognitive Z-score
Mini Balance Evaluation Systems Test (Mini-BESTest)
+3 more
Secondary outcome measures
Short Activities-specific Balance Confidence Scale Score

Side effects data

From 2022 Phase 1 & 2 trial • 14 Patients • NCT04325503
29%
Nausea
14%
Mild Nasal Congestion
14%
Headache
14%
Vivid dreams
7%
Change in Blood Glucose Level
7%
Mild Changes to Bowel Movement
7%
Anxiety
100%
80%
60%
40%
20%
0%
Study treatment Arm
Carbidopa and Carbidopa-Levodopa Treatment

RES Trial Design

1Treatment groups
Experimental Treatment
Group I: TreatmentExperimental Treatment1 Intervention
carbidopa and carbidopa-levodopa treatment for parkinsonian signs in older persons using standard dosing, frequency for a duration for 1-2 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
carbidopa
2019
Completed Phase 2
~180

Find a Location

Who is running the clinical trial?

National Institute on Aging (NIA)NIH
1,660 Previous Clinical Trials
28,004,845 Total Patients Enrolled
1 Trials studying Parkinsonism
3,500 Patients Enrolled for Parkinsonism
University of MichiganLead Sponsor
1,787 Previous Clinical Trials
6,365,520 Total Patients Enrolled
Nicolaas Bohnen, MDPrincipal Investigator - University of Michigan
University of Michigan C.S. Mott Children's Hospital, University of Michigan Hospital, VA Ann Arbor Healthcare System, Von Voigtlander Women's Hospital
Katholieke University (Medical School)
University Of Mi Hosps (Residency)
2 Previous Clinical Trials
28 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~3 spots leftby Mar 2025